Zanaflex
Product Images NDC 16590-871

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 16590-871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Zanaflex 4mg Lab 871)

Label Image (Zanaflex 4mg Lab 871)
This is the description of a medication called Ganesil by a company called Acorda Therapeutic. The medication comes in capsules, with each capsule containing 458 Tzaidie Hel equivalent to 4mg of Tzaniine base. The medication label warns that consuming alcohol with the medication may intensify its effect and advises users to operate machinery with caution. The label also discloses that consuming the medication may cause drowsiness. The medication is packaged in the USA, and its GTY B S TAT RL USA Gresss, while its National Drug Code (NDC) is 16590-871-62 s. No information is available regarding the medication's application or intended use.*
FDA Label Image

Label Image (Zanaflex 6mg Lab 756)

Label Image (Zanaflex 6mg Lab 756)
This is a partial drug label. It contains information about a medication called "e BRSTAT BUSA Gnempe". The drug comes in a capsule form and one capsule contains 0.67mg Tranidine which is equivalent to 6mg tiza base. The label also includes the NDC number, lot number, and other manufacturing information.*
FDA Label Image

Figure 1 (Zanaflex Fig1)

FDA Label Image

Figure 2 (Zanaflex Fig2)

FDA Label Image

Figure 3 (Zanaflex Fig3)

Figure 3 (Zanaflex Fig3)
The text describes the improvement in Ashworth Score as a result of the use of Tizanidine at a mean dose of 26.8 mg. It shows the scores at the end of titration, end of maintenance, and endpoint at week 3 and week 7, using the last observation carried forward method.*
FDA Label Image

Structure Image (Zanaflex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.